HiberCell, Inc. has acquired the Imprime PGG program from Biothera Pharmaceuticals, Inc.
This website will deactivate on August 31. To learn more visit HiberCell.com

About Biothera Pharmaceuticals

Biothera Pharmaceuticals is developing Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation and infiltration into tumors, and to enhance clinical benefit from immune checkpoint inhibitors.  Biothera Pharmaceuticals is currently developing this platform drug through clinical research collaborations with Merck, Genentech, the Dana Farber Cancer Institute and the Big Ten Cancer Research Consortium in cancers including triple negative breast cancer, advanced melanoma, colorectal cancer and non-small lung cell cancer. Phase 2 studies combining Imprime PGG with pembrolizumab are fully enrolled and provide both clinical and mechanistic proof of concept. Biothera is a privately held immuno-oncology company based in Eagan, MN and retains all commercial rights to Imprime PGG.

For Healthcare Professionals

Steven J. O’Day, M.D. talks about the potential synergies of combining Imprime PGG and checkpoint inhibitor therapy in Biothera’s Phase 2 melanoma/triple negative breast cancer study, IMPRIME 1. Dr. O’Day is the Executive Director of the John Wayne Cancer Institute and Cancer Clinic at Providence Saint John’s Health Center, Director of Providence Los Angeles Regional Research, and a Professor of Medical Oncology.  He is also a Principal Investigator for this study and Chairman of the Trial Steering Committee overseeing the clinical trial. Other brief videos about the study protocol, Imprime PGG’s mechanism of action and the Imprime PGG-specific patient selection biomarker are designed for medical professionals seeking additional information about Biothera’s clinical development program.

Company Spotlight

A recently published study in The Journal of Immunology reports that Imprime PGG administration in healthy human subjects results in innate immune activation. These data also show that Imprime PGG responsiveness is dependent upon the formation of an immune complex between Imprime PGG and endogenous anti-beta glucan antibodies (ABA). ABA levels above or equal to 20mcg/ml are necessary for the formation of the immune complex. This ABA level threshold is currently being used as a patient selection biomarker in Imprime PGG clinical trials. Learn More 

For Patients

Biothera Pharmaceuticals and its research collaborators are currently seeking patients for clinical studies evaluating Imprime PGG and immune checkpoint inhibitor and monoclonal antibody therapies in non small cell lung cancer and colorectal cancer. To learn more about how Imprime PGG works with checkpoint inhibitor therapies to fight cancer, watch this brief non-technical video.

Clinical Collaborations

Biothera Pharmaceuticals has partnered with leading pharmaceutical companies and research organizations to advance Imprime PGG for cancer immunotherapy. We have a series of clinical research collaborations with Merck & Co., Genentech/Roche and AstraZeneca to evaluate Imprime PGG and checkpoint inhibitor therapies (anti-PD-1/anti-PD-L1) in multiple cancer indications.